Imfinzi (durvalumab) Disease area(s): Oncology Manufacturer(s): AstraZeneca 2024 Sales (USD): $4.72 billion Why it sold so well: In 2024, AstraZenecas Imfinzi experienced strong sales growth, driven by expanded indications and robust clinical trial results
ProQuad was first approved by the FDA in September 2005, whereas Varivax was approved by the FDA in March 1995
Tirzepatide offers superior weight loss results through dual hormone receptor activation, while Qsymia provides appetite suppression through neurotransmitter modulation at a lower cost
Exercise can help stimulate bowel motility (especially helpful if constipation is an issue) and is a proven stress-reducer
Key contributors to neuromuscular dysfunction and muscle loss associated with aging Sarcopenia exhibits substantial variability, shaped by genetic, environmental, and epigenetic influences [6]
Quantita-tive PCR was conducted on the cDNA using the 2 Q3 SYBR qPCR Master Mix (ToloBio, 22204-01, China) on an Applied Biosystems 7900HT real-time PCR system (Applied Biosystems, Foster City, CA, USA)
